Mohsin Malik, MD
Dermatology · New London, CTNPI 1376864371
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.2% of the total across 758 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 18.2% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,805, 2.8 times the $1,369 reported in 2019.
Across 758 payments — averaging $21.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- Pfizer$1K
- Amgen$1K
- Regeneron Healthcare Solutions, Inc.$1K
- UCB, Inc.$1K
- Johnson & Johnson$1K
- plus $7K from 27 others
What the payments were for
- Food & beverage$15,85297%
- Education$4573%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 159 | $2,968 |
| Pfizer | 69 | $1,444 |
| Amgen | 68 | $1,439 |
| Regeneron Healthcare Solutions, Inc. | 48 | $1,297 |
| UCB, Inc. | 46 | $1,261 |
| Johnson & Johnson | 33 | $1,051 |
| LEO Pharma Inc. | 49 | $882 |
| Incyte Corporation | 34 | $792 |
| Novartis | 34 | $700 |
| E.r. Squibb & Sons, L.L.C. | 28 | $675 |
| Sanofi | 27 | $633 |
| Lilly USA, LLC | 30 | $618 |
| Sun Pharmaceutical Industries Inc. | 24 | $516 |
| Arcutis Biotherapeutics, Inc. | 26 | $428 |
| Galderma Laboratories, L.p. | 20 | $398 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 13 | $220 |
| Dermavant Sciences, Inc. | 8 | $166 |
| Mayne Pharma Commercial LLC | 7 | $147 |
| Sebela Pharmaceuticals Inc. | 7 | $110 |
| Organon | 5 | $71 |
| Boehringer Ingelheim | 3 | $60 |
| Bristol Myers Squibb | 1 | $59 |
| LNHC, Inc | 3 | $53 |
| Almirall LLC | 3 | $52 |
| Verrica Pharmaceuticals Inc. | 2 | $48 |
| Botanix SB Inc | 2 | $47 |
| Journey Medical Corporation | 2 | $44 |
| EPI Health, LLC | 2 | $38 |
| Genentech USA, Inc. | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Biofrontera Inc. | 1 | $18 |
| Dermira, Inc. | 1 | $16 |
| Gilead | 1 | $16 |
How this compares
$16,309 in reported general payments places this provider in the 80th percentile of 222 dermatology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 14 | $333,953 |
| Dupixent PenDupilumab | 40 | $148,956 |
| Cosentyx Unoready PenSecukinumab | 13 | $116,643 |
| OtezlaApremilast | 22 | $113,693 |
| ZoryveRoflumilast | 26 | $22,704 |
| Tacrolimus | 34 | $6,689 |
| Fluorouracil | 102 | $6,520 |
| Ivermectin | 14 | $5,100 |
| Metronidazole | 79 | $4,536 |
| Calcipotriene | 41 | $3,331 |
| Clobetasol Propionate | 83 | $2,790 |
| Imiquimod | 15 | $2,017 |
| Econazole Nitrate | 43 | $1,461 |
| Ketoconazole | 117 | $1,337 |
| ValacyclovirValacyclovir Hcl | 38 | $1,026 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $1,439 | $113,69322 claims |
| Arcutis Biotherapeutics, Inc.Zoryve | $428 | $22,70426 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 222 dermatology providers in Connecticut.
Other dermatology in New London
- Michael PayetteCromwell$3.2M
- Bruce StroberCromwell$2.9M
- Brett KingFairfield$2.5M
- Mona ShahriariCromwell$2.2M
- Jeremy MossMadison$2M
- Brittany CraiglowFairfield$1.9M
- Meagen McCuskerEnfield$1.8M
- Marcus McFerrenOrange$872K
- Christopher BunickNew Haven$661K
- Keith ChoateNew Haven$362K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.